Podcasts

E-Books

Videos

Articles

Business & Practice

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market access and affordability.

A Closer Look at New FDA Guidance Removing Barriers to Biosimilar Development

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.

BioRationality: The FDA Sets Sights on Removing Clinical Efficacy Studies for Biosimilars

The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US.

FDA Approves Celltrion Aflibercept Biosimilar: Eydenzelt

Biosimilar tocilizumab proves to be a cost-effective treatment for rheumatoid arthritis in Spain, enhancing access to advanced therapies.

Biosimilar Tocilizumab Shows Cost-Effectiveness Advantage in Spanish RA Population

Biosimilars and generics drive significant health care savings, yet a concerning lack of biosimilar development for biologics set to lose exclusivity in the next 10 years threatens future access and affordability.

Biosimilars Drive Savings and Access, Yet Looming Development Gap Threatens Future

Australia's adoption of etanercept biosimilars enhances access to rheumatoid arthritis treatments, maintaining treatment persistence and patient care quality.

Stable Treatment Persistence in RA After Etanercept Biosimilar Introduction in Australia

Recent approvals and settlements enhance global access to aflibercept biosimilars, improving treatment options for age-related macular degeneration and diabetic retinopathy.

Global Aflibercept Biosimilar Progress Signals Rising Access for Retinal Disease Care

The European Commission (EC) approves new biosimilars for osteoporosis and eye conditions, enhancing treatment options and patient access across Europe.

EC Approves New Biosimilars for Bone and Eye Conditions

The FDA has approved Bosaya and Aukelso, expanding affordable denosumab biosimilars for osteoporosis and bone-related cancers and enhancing treatment options.

Policy